Krystal Biotech Q3 product revenue rises 30% on VYJUVEK demand

What happened

Krystal Biotech reported that third-quarter product revenue rose 30% year over year, driven by demand for VYJUVEK, while net income fell as costs and tax expense increased. The company authorized a $400 share repurchase program and expects to launch VYJUVEK in Italy in early 2027.

Confirmed

Global impact / market context

Higher sales alongside lower net income show that rising costs and taxes absorbed part of the revenue growth. The $400 repurchase authorization could direct company cash toward buying its own shares, while future sales depend partly on expanding patient use and launches abroad.

Analyst inference

The update combines evidence of growing US demand and broader prescribing abroad with near-term earnings pressure from higher costs and tax expense. Investors will weigh whether sales growth can outpace spending, including the company’s stated research and selling-cost outlook for 2026.

Analyst inference

What to watch

1. Track whether VYJUVEK patient demand and prescriber numbers continue to grow in the United States, where the company reported more than 760 reimbursement approvals. Confirmed
2. Watch for the planned Italy launch in early 2027 and whether the completed pricing negotiations translate into sales; the launch remains a company expectation. Proposed
3. Compare future revenue growth with operating costs and taxes, since third-quarter net income declined despite higher product revenue; this will indicate whether sales growth improves earnings. Analyst inference

Evidence

• Original source link unavailable